Drug intelligence / Profile preview

Breaze

Development stage: Unknown
Lead developer: Samson Pharmaceutical
Modality: Small Molecules
Administration: Intranasal, Oral

Overview

**Breaze** is a non-specific brand name used for multiple, chemically distinct pharmaceutical products rather than one drug. Documented products include an oral montelukast tablet marketed for asthma prevention and allergic rhinitis; an oral fixed-dose levocetirizine + montelukast tablet for allergic symptoms; and U.S. over-the-counter oxymetazoline hydrochloride nasal sprays for temporary nasal-congestion relief. Consequently, the exact active ingredient, dosage form, route, mechanism, manufacturer, and combination status cannot be assigned uniquely without a formulation qualifier.

Brand names: Breaze

Targets

ADRA1A (α1A)ADRA2A (α2A)CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Breaze.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Breaze.

Explore the full profile